Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)

NCT03591965 is registered in ClinicalTrials.gov with Antengene Therapeutics Limited as lead sponsor.

NCT NCT03591965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03591965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)
Lead sponsor
Antengene Therapeutics Limited
Phase
Phase 2
Overall status
Terminated
Start date
August 7, 2018
Completion date
August 3, 2022
Enrollment
73 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma